High-dose methotrexate in osteogenic sarcoma adjuvant chemotherapy and limb salvage results.
This communication provides a description and update of the three adjuvant regimens utilized at the Sidney Farber Cancer Institute. The disease-free survivals are: Study I--42% at 4 years; Study II--58% at 3 years; and Study III--currently 78%. In the limb salvage experience, among the evaluable patients, 6 of 12 treated with preoperative chemotherapy are disease free (median 32 months) and 12 of 14 (86%) treated without preoperative chemotherapy are disease free (median 13 months).
D000671:Amputation, Surgical; D000792:Angiography; D001859:Bone Neoplasms / Q000098:blood supply / Q000188:drug therapy* / Q000601:surgery; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D005121:Extremities / Q000098:blood supply; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy / Q000556:secondary; D008727:Methotrexate / Q000008:administration & dosage*; D012516:Osteosarcoma / Q000098:blood supply / Q000188:drug therapy* / Q000601:surgery; D013997:Time Factors
D008727:Methotrexate